Literature DB >> 35192623

From viability to cell death: Claims with insufficient evidence in high-impact cell culture studies.

Ali Burak Özkaya1, Caner Geyik2,3.   

Abstract

BACKGROUND: Reliability of preclinical research is of critical concern. Prior studies have demonstrated the low reproducibility of research results and recommend implementing higher standards to improve overall quality and robustness of research. One understudied aspect of this quality issue is the harmony between the research hypotheses and the experimental design in published work. METHODS AND
FINDINGS: In this study we focused on highly cited cell culture studies and investigated whether commonly asserted cell culture claims such as viability, cytotoxicity, proliferation rate, cell death and apoptosis are backed with sufficient experimental evidence or not. We created an open access database containing 280 claims asserted by 103 different high-impact articles as well as the results of this study. Our findings revealed that only 64% of all claims were sufficiently supported by evidence and there were concerning misinterpretations such as considering the results of tetrazolium salt reduction assays as indicators of cell death or apoptosis.
CONCLUSIONS: Our analysis revealed a discordance between experimental findings and the way they were presented and discussed in the manuscripts. To improve quality of pre-clinical research, we require clear nomenclature by which different cell culture claims are distinctively categorized; materials and methods sections to be written more meticulously; and cell culture methods to be selected and utilized more carefully. In this paper we recommend a nomenclature for selected cell culture claims as well as a methodology for collecting evidence to support those claims.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35192623      PMCID: PMC8863264          DOI: 10.1371/journal.pone.0250754

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  18 in total

Review 1.  Reproducibility in science: improving the standard for basic and preclinical research.

Authors:  C Glenn Begley; John P A Ioannidis
Journal:  Circ Res       Date:  2015-01-02       Impact factor: 17.367

2.  Ki67 is a Graded Rather than a Binary Marker of Proliferation versus Quiescence.

Authors:  Iain Miller; Mingwei Min; Chen Yang; Chengzhe Tian; Sara Gookin; Dylan Carter; Sabrina L Spencer
Journal:  Cell Rep       Date:  2018-07-31       Impact factor: 9.423

3.  Accounting Artifacts in High-Throughput Toxicity Assays.

Authors:  Jui-Hua Hsieh
Journal:  Methods Mol Biol       Date:  2016

4.  1,500 scientists lift the lid on reproducibility.

Authors:  Monya Baker
Journal:  Nature       Date:  2016-05-26       Impact factor: 49.962

Review 5.  Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction.

Authors:  Michael V Berridge; Patries M Herst; An S Tan
Journal:  Biotechnol Annu Rev       Date:  2005

6.  How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation.

Authors:  John P A Ioannidis; Betty Y S Kim; Alan Trounson
Journal:  Nat Biomed Eng       Date:  2018-11-08       Impact factor: 25.671

7.  The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells.

Authors:  Ly P Vu; Brian F Pickering; Yuanming Cheng; Sara Zaccara; Diu Nguyen; Gerard Minuesa; Timothy Chou; Arthur Chow; Yogesh Saletore; Matthew MacKay; Jessica Schulman; Christopher Famulare; Minal Patel; Virginia M Klimek; Francine E Garrett-Bakelman; Ari Melnick; Martin Carroll; Christopher E Mason; Samie R Jaffrey; Michael G Kharas
Journal:  Nat Med       Date:  2017-09-18       Impact factor: 53.440

8.  Why most published research findings are false.

Authors:  John P A Ioannidis
Journal:  PLoS Med       Date:  2005-08-30       Impact factor: 11.613

9.  Evidence of Experimental Bias in the Life Sciences: Why We Need Blind Data Recording.

Authors:  Luke Holman; Megan L Head; Robert Lanfear; Michael D Jennions
Journal:  PLoS Biol       Date:  2015-07-08       Impact factor: 8.029

10.  R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling.

Authors:  Rui Su; Lei Dong; Chenying Li; Sigrid Nachtergaele; Mark Wunderlich; Ying Qing; Xiaolan Deng; Yungui Wang; Xiaocheng Weng; Chao Hu; Mengxia Yu; Jennifer Skibbe; Qing Dai; Dongling Zou; Tong Wu; Kangkang Yu; Hengyou Weng; Huilin Huang; Kyle Ferchen; Xi Qin; Bin Zhang; Jun Qi; Atsuo T Sasaki; David R Plas; James E Bradner; Minjie Wei; Guido Marcucci; Xi Jiang; James C Mulloy; Jie Jin; Chuan He; Jianjun Chen
Journal:  Cell       Date:  2017-12-14       Impact factor: 66.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.